ANXA2 was isolated from the serum of aggressive triple-negative breast cancer (TNBC) patients, and high levels of ANXA2 protein or mRNA were found to correlate with the degree of tumor malignancy. Here, ANXA2 is linked to triple-negative breast carcinoma.